Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' CHABOT GG' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 30 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Idres, N; Benoit, G; Flexor, MA; Lanotte, M; Chabot, GG
      Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites

      CANCER RESEARCH
    2. Marill, J; Cresteil, T; Lanotte, M; Chabot, GG
      Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites

      MOLECULAR PHARMACOLOGY
    3. Chabot, GG; Robert, J; Lokiec, F; Canal, P
      Irinotecan pharmacokinetics

      BULLETIN DU CANCER
    4. CHABOT GG
      CLINICAL PHARMACOKINETICS OF IRINOTECAN

      Clinical pharmacokinetics
    5. DAUZONNE D; FOLLEAS B; MARTINEZ L; CHABOT GG
      SYNTHESIS AND IN-VITRO CYTOTOXICITY OF A SERIES OF 3-AMINOFLAVONES

      European journal of medicinal chemistry
    6. MAHNKE Z; STROTKAMP D; ROOS PH; HANSTEIN WG; CHABOT GG; NEF P
      EXPRESSION AND INDUCIBILITY OF CYTOCHROME-P450-3A9 (CYP3A9) AND OTHERMEMBERS OF THE CYP3A-SUBFAMILY IN RAT-LIVER

      Archives of biochemistry and biophysics
    7. BISSERY MC; VRIGNAUD P; LAVELLE F; CHABOT GG
      EXPERIMENTAL ANTITUMOR-ACTIVITY AND PHARMACOKINETICS OF THE CAMPTOTHECIN ANALOG IRINOTECAN (CPT-11) IN MICE

      Anti-cancer drugs
    8. ABIGERGES D; ARMAND JP; CHABOT GG; BRUNO R; BISSERY MC; BAYSSAS M; KLINKALAKL M; CLAVEL M; CATIMEL G
      PHASE-I AND PHARMACOLOGY STUDY OF INTOPLICINE (RP-60475 NSC-645008), A NOVEL TOPOISOMERASE-I AND TOPOISOMERASE-II INHIBITOR, IN CANCER-PATIENTS

      Anti-cancer drugs
    9. CHABOT GG; ARMAND JP; TERRET C; DEFORNI M; ABIGERGES D; WINOGRAD B; IGWEMEZIE L; SCHACTER L; KAUL S; ROPERS J; BONNAY M
      ETOPOSIDE BIOAVAILABILITY AFTER ORAL-ADMINISTRATION OF THE PRODRUG ETOPOSIDE PHOSPHATE IN CANCER-PATIENTS DURING A PHASE-I STUDY

      Journal of clinical oncology
    10. MAHNKE A; ROOS PH; HANSTEIN WG; CHABOT GG
      IN-VIVO INDUCTION OF CYTOCHROME-P450 CYP3A EXPRESSION IN RAT LEUKOCYTES USING VARIOUS INDUCERS

      Biochemical pharmacology
    11. RIBRAG V; MASSAAD L; JANOT F; MORIZET J; GOUYETTE A; CHABOT GG
      MAIN DRUG-METABOLIZING ENZYME-SYSTEMS IN HUMAN NON-HODGKINS-LYMPHOMASSENSITIVE OR RESISTANT TO CHEMOTHERAPY

      Leukemia & lymphoma
    12. CATIMEL G; CHABOT GG; GUASTALLA JP; DUMORTIER A; COTE C; ENGEL C; GOUYETTE A; MATHIEUBOUE A; MAHJOUBI M; CLAVEL M
      PHASE-I AND PHARMACOKINETIC STUDY OF IRINOTECAN (CPT-11) ADMINISTEREDDAILY FOR 3 CONSECUTIVE DAYS EVERY 3 WEEKS IN PATIENTS WITH ADVANCED SOLID TUMORS

      Annals of oncology
    13. CHABOT GG; ABIGERGES D; CATIMEL G; CULINE S; DEFORNI R; EXTRA JM; MAHJOUBI H; HERAIT P; ARMAND JP; BUGAT R; CLAVEL M; MARTY ME
      POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN (CPT-11) AND ACTIVE METABOLITE SN-38 DURING PHASE-I TRIALS

      Annals of oncology
    14. ABIGERGES D; CHABOT GG; ARMAND JP; HERAIT P; GOUYETTE A; GANDIA D
      PHASE-I AND PHARMACOLOGICAL STUDIES OF THE CAMPTOTHECIN ANALOG IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN CANCER-PATIENTS

      Journal of clinical oncology
    15. CHABOT GG
      LIMITED SAMPLING MODELS FOR SIMULTANEOUS ESTIMATION OF THE PHARMACOKINETICS OF IRINOTECAN AND ITS ACTIVE METABOLITE SN-38

      Cancer chemotherapy and pharmacology
    16. DEFORNI M; CHABOT GG; ARMAND JP; GOUYETTE A; KLINKALAK M; RECONDO G
      PHASE-I AND PHARMACOLOGY STUDY OF FLAVONE ACETIC-ACID ADMINISTERED 2 OR 3 TIMES WEEKLY WITHOUT ALKALINIZATION

      Cancer chemotherapy and pharmacology
    17. PARISE O; JANOT F; LUBOINSKI B; MASSAAD L; ALBIN N; TOUSSAINT C; VERJUS MA; BONNAY M; GOUYETTE A; CHABOT GG
      THYMIDYLATE SYNTHASE ACTIVITY, FOLATES, AND GLUTATHIONE SYSTEM IN HEAD AND NECK-CARCINOMA AND ADJACENT TISSUES

      Head & neck
    18. MUNCK JN; ROUGIER P; CHABOT GG; RAMIREZ LH; BOGNEL C; LUMBROSO J; HERAIT P; ELIAS D; LASSER P; GOUYETTE A
      PHASE-I AND PHARMACOLOGICAL STUDY OF INTRAARTERIAL HEPATIC ADMINISTRATION OF PIRARUBICIN IN PATIENTS WITH ADVANCED HEPATIC METASTASES

      European journal of cancer
    19. TOUSSAINT C; IZZO J; SPIELMANN M; MERLE S; MAYLEVIN F; ARMAND JP; LACOMBE D; TURSZ T; SUNDERLAND M; CHABOT GG; CVITKOVIC E
      PHASE I II TRIAL OF CONTINUOUS-INFUSION VINORELBINE FOR ADVANCED BREAST-CANCER/

      Journal of clinical oncology
    20. MASSAAD L; CHABOT GG; TOUSSAINT C; KOSCIELNY S; MORIZET J; BISSERY MC; GOUYETTE A
      INFLUENCE OF TUMOR SIZE ON THE MAIN DRUG-METABOLIZING ENZYME-SYSTEMS IN MOUSE COLON ADENOCARCINOMA CO38

      Cancer chemotherapy and pharmacology
    21. CHABOT GG
      FACTORS INVOLVED IN CLINICAL-PHARMACOLOGY VARIABILITY IN ONCOLOGY

      Anticancer research
    22. RIBRAG V; MASSAAD L; JANOT F; BISSERY MC; PARISE O; GOUYETTE A; CHABOT GG
      PRINCIPAL DRUG-METABOLIZING ENZYME-SYSTEMS IN L1210 LEUKEMIA SENSITIVE OR RESISTANT TO BCNU IN-VIVO

      Leukemia research
    23. DEFORNI M; BUGAT R; CHABOT GG; CULINE S; EXTRA JM; GOUYETTE A; MADELAINE I; MARTY ME; MATHIEUBOUE A
      PHASE-I AND PHARMACOKINETIC STUDY OF THE CAMPTOTHECIN DERIVATIVE IRINOTECAN, ADMINISTERED ON A WEEKLY SCHEDULE IN CANCER-PATIENTS

      Cancer research
    24. ABIGERGES D; ARMAND JP; CHABOT GG; DACOSTA L; FADEL E; COTE C; HERAIT P; GANDIA D
      IRINOTECAN (CPT-11) HIGH-DOSE ESCALATION USING INTENSIVE HIGH-DOSE LOPERAMIDE TO CONTROL DIARRHEA

      Journal of the National Cancer Institute
    25. DEFORNI M; CHABOT GG; ARMAND JP; FONTANA X; RECONDO G; DOMENGE C; CARDE P; BARBU M; GOUYETTE A
      PHASE-I AND PHARMACOKINETIC STUDY OF BREQUINAR (DUP-785 NSC-368390) IN CANCER-PATIENTS

      European journal of cancer
    26. RIBRAG V; DROZ JP; MORIZET J; LECLERCQ B; GOUYETTE A; CHABOT GG
      TEST DOSE-GUIDED ADMINISTRATION OF CISPLATIN IN AN ANEPHRIC PATIENT -A CASE-REPORT

      Annals of oncology
    27. JANOT F; MASSAAD L; RIBRAG V; DEWAZIERS I; BEAUNE PH; LUBOINSKI B; PARISE O; GOUYETTE A; CHABOT GG
      PRINCIPAL XENOBIOTIC-METABOLIZING ENZYME-SYSTEMS IN HUMAN HEAD AND NECK SQUAMOUS-CELL CARCINOMA

      Carcinogenesis
    28. TOUSSAINT C; ALBIN N; MASSAAD L; GRUNENWALD D; PARISE O; MORIZET J; GOUYETTE A; CHABOT GG
      MAIN DRUG-METABOLIZING AND CARCINOGEN-METABOLIZING ENZYME-SYSTEMS IN HUMAN NONSMALL CELL LUNG-CANCER AND PERITUMORAL TISSUES

      Cancer research
    29. ALBIN N; MASSAAD L; TOUSSAINT C; MATHIEU MC; MORIZET J; PARISE O; GOUYETTE A; CHABOT GG
      MAIN DRUG-METABOLIZING ENZYME-SYSTEMS IN HUMAN BREAST-TUMORS AND PERITUMORAL TISSUES

      Cancer research
    30. MASSAAD L; DEWAZIERS I; RIBRAG V; JANOT F; MORIZET J; BEAUNE PH; GOUYETTE A; CHABOT GG
      SCREENING OF MAIN DRUG-METABOLIZING-ENZYMES IN MOUSE AND HUMAN COLON TUMORS

      Bulletin du cancer


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/10/20 alle ore 15:49:57